Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Complete Resolution of Bulky Cutaneous Squamous Cell Carcinoma by Programmed Death-1 Inhibitor

Published:2024-03-01 Issue:3 Volume:3 Page:
ISSN:2767-7672
Container-title:Annals of Internal Medicine: Clinical Cases
language:en
Short-container-title:AIM Clinical Cases

Author:

Thakker Sach¹^ORCID,Al-Mondhiry Jafar²³^ORCID

Affiliation:

1. Georgetown University School of Medicine, Washington, DC

2. Inova Schar Cancer Institute, Fairfax, Virginia

3. University of Virginia School of Medicine, Charlottesville, Virginia

Publisher

American College of Physicians

Link

https://www.acpjournals.org/doi/pdf/10.7326/aimcc.2023.0570

Reference5 articles.

1. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma

2. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

3. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

4. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP